At a Glance
- Status: Completed Consortium
- Year Launched: 2004
- Initiating Organization: The Sanger Institute
- Initiator Type: Industry
- Disease focus:
- Location: Europe
The Bloodomics project was implemented by the Sanger Institute with the aim of discovering novel gene regulating platelets. This is crucial to understanding what makes blood clots more likely in certain people and, in turn, could provide potential therapeutic targets for treatment of cardiovascular disease. The Sanger Institute uses genome sequences to advance understanding of the biology of humans and pathogens to improve human health.
The aims of the Bloodomics project were to discover genetic markers for the prediction of thrombus formation in coronary artery disease and to design anti-thrombotics for improved prevention treatment.
Bloodomics began in June 2004 and ran for four years.
Structure & Governance
Bloodomics was a consortium project of the Sanger Institute, which receives a recurrent core grant from the Wellcome Trust. The project built on a broad support from the partners' institutions and from other fund- providers across Europe, like the British and Dutch Heart Foundations and National Blood Services.
The Bloodomics project was funded with 9 million Euro through the 6th Framework Program of the European Union
HaemAtlas data (Watkins et al, Blood, 2009) and the platelet whole genome expression data of the Platelet Function cohort (Goodall et al, Blood, 2010) have been deposited with Array Express at EBI and the accession numbers can be found in the respective publications.
Most recent publication regarding genetic markers found for blood clot may be viewed at http://www.sanger.ac.uk/about/press/2010/101126.html (Goodall et al, Blood, 2010)
Points of Contact
Wellcome Trust Sanger Institute
Wellcome Genome Campus
Tel: +44 (0)1223 834244
Fax: +44 (0)1223 494919
(Out of hours contact: +44 (0)1223 495015)